AMENDMENTS TO THE CLAIMS

Please enter the following amendments to the claims

Claims 1.-29. (canceled)

30. (currently amended) A method for treating female sexual ~~dysfunction~~ arousal disorder comprising the step of delivering to a female suffering from female sexual ~~dysfunction~~ arousal disorder a therapeutically effective amount of a neuropeptide Y inhibitor, wherein said ~~inhititor~~ inhibitor is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.

31. (previously presented) The method according to claim 30 wherein said inhibitor has a selective effect on the genitalia of said female.

32. (previously presented) The method according to claim 30 wherein in the absence of sexual stimulation the inhibitor has no or a negligible effect in causing an increase in genital blood flow in said female.

33. (previously presented) The method according to claim 30 wherein said neuropeptide Y is a mediator of genital vasorelaxation.

34. (currently amended) The method according to ~~Claim~~ claim 30 wherein said neuropeptide Y inhibitor is a mediator of vaginal or clitoral vasorelaxation.

35. (currently amended) The method according to ~~Claim~~ claim 30 wherein said neuropeptide Y inhibitor is delivered before or during sexual stimulation.

36. (canceled)

37. (previously presented) The method according to claim 30 wherein said amount of neuropeptide Y inhibitor delivered causes potentiation of cAMP.

38. (previously presented) The method according to claim 37 wherein said cAMP is endogenous cAMP.

39. (previously presented) The method according to claim 30 wherein said inhibitor has a K_i value of less than about 100 nM.

40. (previously presented) The method according to claim 30 wherein said inhibitor has a K_i value of less than about 75 nM.

41. (previously presented) The method according to claim 30 wherein said inhibitor has a K_i value of less than about 50 nM.

42. (previously presented) The method according to claim 30 wherein said inhibitor has a K_i value of less than about 25 nM.

43. (previously presented) The method according to claim 30 wherein said inhibitor has a K_i value of less than about 20 nM.

44. (previously presented) The method according to claim 30 wherein said inhibitor has a K_i value of less than about 15 nM.

45. (previously presented) The method according to claim 30 wherein said inhibitor has a K_i value of less than about 10 nM.

46. (previously presented) The method according to claim 30 wherein said inhibitor has a K_i value of less than about 5 nM.

47. (previously presented) The method according to claim 30 wherein said inhibitor is delivered in combination with one or more other pharmaceutically active agents.

48. (previously presented) The method according to claim 30 wherein said NPY is neuropeptide Y Y1.

49. (previously presented) A method for treating female sexual arousal disorder comprising the step of orally delivering to a female suffering from female sexual arousal disorder a therapeutically effective amount of a neuropeptide Y inhibitor, wherein said inhibitor is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.

50. (previously presented) The method according to claim 49 wherein said inhibitor has a selective effect on the genitalia of said female.

51. (previously presented) The method according to claim 49 wherein in the absence of sexual stimulation said inhibitor has no or a negligible effect in causing an increase in genital blood flow in said female.

52. (previously presented) The method according to claim 49 wherein said neuropeptide Y inhibitor is a mediator of genital vasorelaxation.

53. (previously presented) The method according to Claim 49 wherein said neuropeptide Y inhibitor is a mediator of vaginal or clitoral vasorelaxation.

54. (previously presented) The method according to claim 49 wherein said neuropeptide Y inhibitor is administered orally.

55. (previously presented) The method according to Claim 49 wherein said neuropeptide Y inhibitor is delivered before or during sexual stimulation.

56. (previously presented) The method according to claim 49 wherein said amount of inhibitor causes potentiation of cAMP in the genitalia of said female.

57. (previously presented) The method according to claim 56 where said cAMP is endogenous cAMP.

58. (previously presented) The method according to claim 49 wherein said inhibitor has a K_i value of less than about 100 nM.

59. (previously presented) The method according to claim 49 wherein said inhibitor has a K_i value of less than about 75 nM.

60. (previously presented) The method according to claim 49 wherein said inhibitor has a K_i value of less than about 50 nM.

61. (previously presented) The method according to claim 49 wherein said inhibitor has a K_i value of less than about 25 nM.

62. (previously presented) The method according to claim 49 wherein said inhibitor has a K_i value of less than about 20 nM.

63. (previously presented) The method according to claim 49 wherein said inhibitor has a K_i value of less than about 15 nM.

64. (previously presented) The method according to claim 49 wherein said inhibitor has a K_i value of less than about 10 nM.

65. (previously presented) The method according to claim 49 wherein said inhibitor has a K_i value of less than about 5 nM.

66. (previously presented) The method according to claim 49 wherein said inhibitor is delivered in combination with one or more other pharmaceutically active agents.

67. (previously presented) The method according to claim 49 wherein said NPY is neuropeptide Y Y1.